The faculties at Indiana University Medical Center (IUMC) have continued to contribute scientifically and administrative to ECOG. Dr. Patrick Loehrer, Sr., has been the principal investigator in this past grant period during which time he has served on a Nominating Committee, Fiscal Oversight Committee, Audit Committee, Board of Advisors, and on the ECOG Research Foundation Board. In addition, he has served as the Database Co-chair for the Genitourinary Committee and Chairman of the Testis Cancer Subcommittee. Several other current and past faculty have served or serve in leadership roles in ECOG including current faculty and members of lUMC: George Sledge (Chair: Breast Committee); Melody Cobleigh (Chair: Breast Endocrine Subcommittee), Cheryl Rutledge (Chair: Nursing Committee); Chris Fausel (Chair: Pharmacy Committee); Richard Foster (Co-Chair: Testicular Cancer Subcommittee), and Philip Bonomi (Chair, Non-Small Cell Lung). IUMC faculty has also taken the lead as principal investigators or co-PIs in a number of important Phase II and III trials. A few examples of Phase III trials include: Leukemia (E3999), Breast (E2100, E2193), Gynecologic (GLAP-2, GO 179), Testis (E3894), Renal Cell (E2898), and Pancreas (E4201). Several principal investigators and disciplines other than Medical Oncology emphasize broader participation of our faculty. Dr. Richard Foster, an urologist, is PI of the Intergroup trial on clinical stage I testicular cancer (E8897) and Dr. Higinia Cardenes, a radiation oncologist from IUMC, is PI of two Intergroup trials (GALP-2, G0179) and co-PI on E4201. In the clinical research arena, increased competition for clinical trial accrual exists in the community. During the past grant period, several affiliate members have been added in an effort to promote accrual. This includes the Goshen Hospitals, which is located in Northwestern Indiana, which serves the unique population of the Amish. Accrual to socially disadvantaged population has been problematic for a variety of reasons, most of which are surrounded by multiple medical problems which make eligibility and compliance an issue. Recently Dr. Loehrer has assigned himself to staff the Oncology Clinic at Wishard Hospital, a county hospital with a large minority patient population. In addition, Dr. Kathy Miller has been assigned to run a Breast Cancer Clinic at the same hospital. The clinic is staffed with several African-American support staff (i.e., nurse, research nurse, and social worker) that clearly understands the importance of providing access to clinical research trials to this socially and economically disadvantaged population.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA049883-20
Application #
7426338
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
1989-05-01
Project End
2010-04-30
Budget Start
2008-05-01
Budget End
2009-04-30
Support Year
20
Fiscal Year
2008
Total Cost
$278,182
Indirect Cost
Name
Indiana University-Purdue University at Indianapolis
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
603007902
City
Indianapolis
State
IN
Country
United States
Zip Code
46202
Ignatz-Hoover, James J; Wang, Victoria; Mackowski, Nathan M et al. (2018) Aberrant GSK3? nuclear localization promotes AML growth and drug resistance. Blood Adv 2:2890-2903
Gravis, Gwenaelle; Boher, Jean-Marie; Chen, Yu-Hui et al. (2018) Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies. Eur Urol 73:847-855
Cohee, Andrea A; Bigatti, Silvia M; Shields, Cleveland G et al. (2018) Quality of Life in Partners of Young and Old Breast Cancer Survivors. Cancer Nurs 41:491-497
Partridge, Ann H; Sepucha, Karen; O'Neill, Anne et al. (2017) Does biomarker information impact breast cancer patients' preferences and physician recommendation for adjuvant chemotherapy? Breast Cancer Res Treat 165:545-553
Schneider, Bryan P; Shen, Fei; Jiang, Guanglong et al. (2017) Impact of Genetic Ancestry on Outcomes in ECOG-ACRIN-E5103. JCO Precis Oncol 2017:
Schneider, Bryan P; Shen, Fei; Gardner, Laura et al. (2017) Genome-Wide Association Study for Anthracycline-Induced Congestive Heart Failure. Clin Cancer Res 23:43-51
Vaz-Luis, Ines; O'Neill, Anne; Sepucha, Karen et al. (2017) Survival benefit needed to undergo chemotherapy: Patient and physician preferences. Cancer 123:2821-2828
Cohee, Andrea A; Adams, Rebecca N; Fife, Betsy L et al. (2017) Relationship Between Depressive Symptoms and Social Cognitive Processing in Partners of Long-Term Breast Cancer Survivors. Oncol Nurs Forum 44:44-51
Cohee, Andrea A; Adams, Rebecca N; Johns, Shelley A et al. (2017) Long-term fear of recurrence in young breast cancer survivors and partners. Psychooncology 26:22-28
Haas, Naomi B; Manola, Judith; Uzzo, Robert G et al. (2016) Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 387:2008-16

Showing the most recent 10 out of 87 publications